Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca 2+ release

Nature Medicine

Volumn 17, Issue 8, 2011, Pages 1003-1009

  Zhou, Qiang ^a,b,g   Xiao, Jianmin ^a,g,h   Jiang, Dawei ^a   Wang, Ruiwu ^a   Vembaiyan, Kannan ^a   Wang, Aixia ^a   Smith, Chris D ^a   Xie, Cuihong ^a,b,g   Chen, Wenqian ^a   Zhang, Jingqun ^b   Tian, Xixi ^a   Jones, Peter P ^a,g,i   Zhong, Xiaowei ^a   Guo, Ang ^c   Chen, Haiyan ^b   Zhang, Lin ^a   Zhu, Weizhong ^d   Yang, Dongmei ^e   Li, Xiaodong ^f   Chen, Ju ^f   Gillis, Anne M ^a   Duff, Henry J ^a   Cheng, Heping ^e,g,j   Feldman, Arthur M ^d   Song, Long Sheng ^c   Fill, Michael ^b   Back, Thomas G ^a   Chen, S R Wayne ^a,b   more..

^a UNIVERSITY OF CALGARY   (Canada)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^h Taiping People's Hospital of Dongguan)   (China)

ⁱ UNIVERSITY OF OTAGO   (New Zealand)

^j PEKING UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ION; CARVEDILOL; METOPROLOL; RYANODINE RECEPTOR; UNCLASSIFIED DRUG; VK II 86;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; CALCIUM TRANSPORT; DRUG ACTIVITY; HEART MUSCLE CELL; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; BISOPROLOL; CALCIUM; CALCIUM CHANNEL BLOCKERS; CARBAZOLES; CELL LINE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; GENE KNOCK-IN TECHNIQUES; HUMANS; METOPROLOL; MICE; MICE, MUTANT STRAINS; MICROSCOPY, CONFOCAL; MUTATION, MISSENSE; PROPANOLAMINES; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

MUS;

EID: 79961153702     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2406     Document Type: Article

References (53)

1. Waldo, A.L. et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348, 7-12 (1996). (Pubitemid 26237238)
2. Miller, L.W. Limitations of current medical therapies for the treatment of heart failure. Rev. Cardiovasc. Med. 4 (Suppl. 2), S21-S29 (2003). (Pubitemid 36701294)
3. Kamath, G.S. & Mittal, S. The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death. Prog. Cardiovasc. Dis. 50, 439-448 (2008). (Pubitemid 351636106)
4. Poole-Wilson, P.A. et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362, 7-13 (2003). (Pubitemid 36835815)
5. Stroe, A.F. & Gheorghiade, M. Carvedilol: beta-blockade and beyond. Rev. Cardiovasc. Med. 5 (Suppl. 1), S18-S27 (2004).
6. Greenberg, B. Nonselective versus selective beta-blockers in the management of chronic heart failure: clinical implications of the carvedilol or Metoprolol European Trial. Rev. Cardiovasc. Med. 5 (Suppl. 1), S10-S17 (2004). (Pubitemid 38811475)
7. Remme, W.J. Which beta-blocker is most effective in heart failure? Cardiovasc. Drugs Ther. 24, 351-358 (2010).
8. Hjalmarson, A. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Basic Res. Cardiol. 95 (Suppl. 1), I41-I45 (2000).
9. Foody, J.M., Farrell, M.H. & Krumholz, H.M. beta-blocker therapy in heart failure: scientific review. J. Am. Med. Assoc. 287, 883-889 (2002). (Pubitemid 34252037)
10. Kukin, M.L. et al. Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure. Am. J. Cardiol. 77, 486-491 (1996). (Pubitemid 26086637)
11. Thomson, M.J., Puntmann, V. & Kaski, J.C. Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment? Cardiovasc. Drugs Ther. 21, 195-210 (2007). (Pubitemid 46817482)
12. Bers, D.M. Calcium and cardiac rhythms: physiological and pathophysiological. Circ. Res. 90, 14-17 (2002). (Pubitemid 34074602)
13. Pogwizd, S.M. & Bers, D.M. Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc. Med. 14, 61-66 (2004). (Pubitemid 38340848)
14. Engelhardt, S. et al. Altered calcium handling is critically involved in the cardiotoxic effects of chronic β-adrenergic stimulation. Circulation 109, 1154-1160 (2004). (Pubitemid 38332620)
15. Jiang, D. et al. RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR). Proc. Natl. Acad. Sci. USA 101, 13062-13067 (2004). (Pubitemid 39167583)
16. Jiang, D. et al. Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ. Res. 97, 1173-1181 (2005).
17. Kass, R.S. & Tsien, R.W. Fluctuations in membrane current driven by intracellular calcium in cardiac Purkinje fibers. Biophys. J. 38, 259-269 (1982). (Pubitemid 12019588)
18. Orchard, C.H., Eisner, D. & Allen, D. Oscillations of intracellular Ca2+ in mammalian cardiac muscle. Nature 304, 735-738 (1983). (Pubitemid 13037721)
19. Stern, M.D., Kort, A., Bhatnagar, G. & Lakatta, E. Scattered-light intensity fluctuations in diastolic rat cardiac muscle caused by spontaneous Ca++-dependent cellular mechanical oscillations. J. Gen. Physiol. 82, 119-153 (1983). (Pubitemid 13034088)
20. Wier, W.G., Kort, A., Stern, M., Lakatta, E. & Marban, E. Cellular calcium fluctuations in mammalian heart: direct evidence from noise analysis of aequorin signals in Purkinje fibers. Proc. Natl. Acad. Sci. USA 80, 7367-7371 (1983). (Pubitemid 14208859)
21. Marban, E., Robinson, S.W. & Wier, W.G. Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle. J. Clin. Invest. 78, 1185-1192 (1986). (Pubitemid 17181555)
22. Schlotthauer, K. & Bers, D.M. Sarcoplasmic reticulum Ca2+ release causes myocyte depolarization. Underlying mechanism and threshold for triggered action potentials. Circ. Res. 87, 774-780 (2000).
23. Xie, L.H. & Weiss, J.N. Arrhythmogenic consequences of intracellular calcium waves. Am. J. Physiol. Heart Circ. Physiol. 297, H997-H1002 (2009).
24. Cerrone, M. et al. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ. Res. 96, e77-e82 (2005).
25. Liu, N. et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ. Res. 99, 292-298 (2006). (Pubitemid 44174937)
26. Cerrone, M. et al. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ. Res. 101, 1039-1048 (2007). (Pubitemid 350084981)
27. Paavola, J. et al. Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves. Eur. Heart J. 28, 1135-1142 (2007). (Pubitemid 47343860)
28. Kannankeril, P.J. et al. Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc. Natl. Acad. Sci. USA 103, 12179-12184 (2006). (Pubitemid 44215831)
29. Uchinoumi, H. et al. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor. Circ. Res. 106, 1413-1424 (2010).
30. Vermeulen, J.T. et al. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc. Res. 28, 1547-1554 (1994). (Pubitemid 24318270)
31. Shannon, T.R., Pogwizd, S.M. & Bers, D.M. Elevated sarcoplasmic reticulum Ca2+ leak in intact ventricular myocytes from rabbits in heart failure. Circ. Res. 93, 592-594 (2003). (Pubitemid 37222154)
32. Priori, S.G. et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 106, 69-74 (2002). (Pubitemid 34747444)
33. Hayashi, M. et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 119, 2426-2434 (2009).
34. Neugebauer, G., Akpan, W., von Mollendorff, E., Neubert, P. & Reiff, K. Pharmacokinetics and disposition of carvedilol in humans. J. Cardiovasc. Pharmacol. 10 (Suppl. 11), S85-S88 (1987).
35. Tenero, D. et al. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J. Clin. Pharmacol. 40, 844-853 (2000).
36. Watanabe, H. et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat. Med. 15, 380-383 (2009).
37. Hilliard, F.A. et al. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. J. Mol. Cell. Cardiol. 48, 293-301 (2010).
38. Hwang, H.S. et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ. Arrhythm Electrophysiol. 4, 128-135 (2011).
39. Echt, D.S. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 324, 781-788 (1991).
40. Reiken, S. et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107, 2459-2466 (2003). (Pubitemid 36605229)
41. Mochizuki, M. et al. Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure. J. Am. Coll. Cardiol. 49, 1722-1732 (2007). (Pubitemid 46589924)
42. Doze, P. et al. Synthesis and evaluation of radiolabeled antagonists for imaging of beta-adrenoceptors in the brain with PET. Neurochem. Int. 40, 145-155 (2002). (Pubitemid 34019191)
43. Caron, G. et al. Structure-lipophilicity relationships of neutral and protonated beta-blockers, part I, intra-and intermolecular effects in isotropic solvent systems. Helv. Chim. Acta 82, 1211-1222 (1999). (Pubitemid 29402121)
44. Fujimaki, M. Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. Chirality 4, 148-154 (1992).
45. Stahl, E., Mutschler, E., Baumgartner, U. & Spahn-Langguth, H. Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues. Arch. Pharm. (Weinheim) 326, 529-533 (1993). (Pubitemid 23287141)
46. Yao, A. et al. Characteristic effects of α1-β1,2-adrenergic blocking agent, carvedilol, on [Ca2+]i in ventricular myocytes compared with those of timolol and atenolol. Circ. J. 67, 83-90 (2003). (Pubitemid 36123990)
47. Ko, D.T. et al. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch. Intern. Med. 164, 1389-1394 (2004). (Pubitemid 38937849)
48. McMurray, J. et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J. Am. Coll. Cardiol. 45, 525-530 (2005). (Pubitemid 40222245)
49. Yue, T.L. et al. Carvedilol, a new vasodilator and β adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther. 263, 92-98 (1992).
50. Ohlstein, E.H. et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc. Natl. Acad. Sci. USA 90, 6189-6193 (1993). (Pubitemid 23191480)
51. Okafor, C.C. et al. Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. BMC Physiol. 3, 6 (2003).
52. Hunt, D.J. et al. K201 (JTV519) suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2 irrespective of FKBP12.6 association. Biochem. J. 404, 431-438 (2007). (Pubitemid 46953917)
53. Chen, B., Wu, Y., Mohler, P.J., Anderson, M.E. & Song, L.S. Local control of Ca2+-induced Ca2+ release in mouse sinoatrial node cells. J. Mol. Cell. Cardiol. 47, 706-715 (2009).